AMWatch

Venturefonde fravælger diagnostikfirmaer: Der er ikke mange succeser

Det er så svært at få succes med diagnostiske produkter, at flere venturefonde har fraprioriteret området som et investeringsemne. To af dem er danske Novo Seeds og Sunstone Capital.

Søren Møller, managing partner i Novo Seeds, mener, at diagnostikselskaber har en svær forretningsmodel at arbejde med. | Photo: Novo Nordisk Fonden

Mens de færreste nok vil sige, at det er let at rejse penge inden for life science-branchen i det hele taget, så har diagnostikselskaber et særligt sæt udfordringer. Specielt i Danmark, hvor storinvestorerne ikke vil lege med.

Hos både Novo Seeds og Sunstone Capital har man bevidst fravalgt at investere i den slags virksomheder og fokuserer i stedet på terapier og i mindre grad medico.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Norway has the fastest growing investment fund market in Europe

So far in 2021, Norway has experienced massive inflows to its investment fund markets, beating former records. The pandemic and different government initiatives have resulted in an increased savings rate. Data also show that market shares are shifting among Norwegian fund managers.

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch